Patents by Inventor Michael Briskin

Michael Briskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS
    Publication number: 20120087934
    Abstract: The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Edward J. Stewart, Michael Briskin
  • METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTRATION OF ALPHA-FETOPROTEIN IN COMBINATION WITH AN INTEGRIN ANTAGONIST
    Publication number: 20100150915
    Abstract: The present invention relates to methods for treating multiple sclerosis by administering therapeutically effective amounts of an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and an integrin antagonist (e.g., natalizumab) to a patient in need thereof. Also disclosed are compositions and kits that comprise therapeutically effective amounts of an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and an integrin antagonist (e.g., natalizumab).
    Type: Application
    Filed: February 20, 2008
    Publication date: June 17, 2010
    Inventors: Edward J. Stewart, Michael Briskin
  • COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS
    Publication number: 20100028297
    Abstract: The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 4, 2010
    Inventors: Edward J. Stewart, Michael Briskin
  • Mucosal vascular addressins and uses thereof
    Publication number: 20070178089
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments that selectively bind human MAdCAM.
    Type: Application
    Filed: April 3, 2007
    Publication date: August 2, 2007
    Inventors: Michael Briskin, Douglas Ringler, Dominic Picarella, Walter Newman
  • Mucosal vascular addressins and uses thereof
    Publication number: 20060057135
    Abstract: The present invention relates to pharmaceutical compositions which comprise an antibody and/or antigen-binding fragments which have the epitopic specificity of ACT-1 monoclonal antibody.
    Type: Application
    Filed: November 1, 2005
    Publication date: March 16, 2006
    Inventors: Michael Briskin, Douglas Ringler, Dominic Picarella, Walter Newman